2024
January
CD4+ T cells wear many hats
January 31, 2024
CD4+ T cells are best known for their roles in helping CD8+ T cells, but in recent years, researchers have identified CD4+ T cells across broad ranges of subsets playing roles in activation, recruitment, reprogramming, and direct cytotoxicicity. To better understand these CD4+ T cell roles and their contributions to antitumor immunity, Bawden...
Antitumor T cell responses detected in patients with new vaccine strategy in immune-cold tumors
January 24, 2024
Colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC) have a low survival rate, low infiltration of tumor-specific tumor-infiltrating lymphocytes (TIL), infrequent neoantigen mutations, and checkpoint inhibitors are largely ineffective in PDAC and subtypes of CRC. Common mutations in the oncogenes driver KRAS (mKRAS) however can serve as immunotherapy targets. Pant et al. conducted...
You can’t kill what you can't find: dormant disseminated tumor cells (DTCs) evade T cells through “relative scarcity”
January 17, 2024
Surviving breast cancer is an incredible feat, but patients whose initial tumors are successfully cleared still face a high risk of recurrence, even years after initial treatment. Tumor recurrence can be attributed to the presence of dormant disseminated tumor cells (DTCs) that hide out in the body and can potentially seed new tumors...
No more luck of the draw: new predictive signature for efficacy PD-1 blockade
January 10, 2024
Despite its successes in some patients, immune checkpoint blockade (ICB) targeting PD-1 is not beneficial in most patients with non-small cell lung cancer (NSCLC). Determining which patients would or would not benefit from this treatment has remained a challenge. Previously, a dysfunctional T cell subset has been associated with response to treatment, but...
